| Assay ID | Title | Year | Journal | Article |
|---|
| AID300533 | Inhibition of human recombinant MMP2 | 2007 | Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
| Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. |
| AID261913 | Inhibition of LPS-stimulated TNF production in THP cells at 3 uM | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID281652 | Inhibition of LPS-stimulated TNFalpha production in mouse model at 10 mg/kg, po at 1 hrs | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
| Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors. |
| AID347022 | Inhibition of MMP13 | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Current perspective of TACE inhibitors: a review. |
| AID300534 | Inhibition of human recombinant MMP13 | 2007 | Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
| Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. |
| AID347020 | Inhibition of MMP2 | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Current perspective of TACE inhibitors: a review. |
| AID281654 | Inhibition of LPS-stimulated TNFalpha production in mouse model at 10 mg/kg, po at 12 hrs | 2004 | Journal of medicinal chemistry, Dec-02, Volume: 47, Issue:25
| Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors. |
| AID261920 | Bioavailability in rat at 10 mg/kg | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID261921 | Bioavailability in dog at 10 mg/kg | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID297910 | Inhibition of TNFalpha production in Sprague-Dawley rat at 10 mg/kg, po administered 1 hr prior to LPS challenge after 1.5 hrs | 2007 | Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
| Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles. |
| AID261912 | Inhibition of MMP13 | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID347029 | Inhibition of MMP1 | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Current perspective of TACE inhibitors: a review. |
| AID261910 | Inhibition of TACE | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID261919 | Bioavailability in mouse at 10 mg/kg | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID300536 | Inhibition of human TACE in human whole blood | 2007 | Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
| Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. |
| AID261911 | Inhibition of MMP1 | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID347023 | Inhibition of TACE | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
| Current perspective of TACE inhibitors: a review. |
| AID300532 | Inhibition of human TACE expressed in CHO cells by FRET assay | 2007 | Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
| Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. |
| AID261914 | Inhibition of LPS-stimulated TNF production in THP cells at 1 uM | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
| Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. |
| AID1798327 | Aggrecanase-1 Inhibition Assay from Article 10.1124/jpet.103.059675: \\Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-conver | 2004 | The Journal of pharmacology and experimental therapeutics, Apr, Volume: 309, Issue:1
| Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheu |
| AID1798326 | MMP Inhibition Assay from Article 10.1124/jpet.103.059675: \\Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzym | 2004 | The Journal of pharmacology and experimental therapeutics, Apr, Volume: 309, Issue:1
| Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheu |
| AID1798328 | TACE Inhibition Assay from Article 10.1016/j.bmc.2007.06.031: \\Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.\\ | 2007 | Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
| Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. |
| AID1798325 | TACE Inhibition Assay from Article 10.1124/jpet.103.059675: \\Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzy | 2004 | The Journal of pharmacology and experimental therapeutics, Apr, Volume: 309, Issue:1
| Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheu |
| AID1798329 | MMP Inhibition Assay from Article 10.1016/j.bmc.2007.06.031: \\Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.\\ | 2007 | Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
| Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2005 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
| Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2005 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
| Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |